{"id":50202,"date":"2025-12-08T22:20:08","date_gmt":"2025-12-08T14:20:08","guid":{"rendered":"https:\/\/flcube.com\/?p=50202"},"modified":"2025-12-08T22:20:16","modified_gmt":"2025-12-08T14:20:16","slug":"leads-biolabs-lbl-034-multiple-myeloma-ash-data-shows-82-orr","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50202","title":{"rendered":"Leads Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR"},"content":{"rendered":"\n<p><strong>Nanjing Leads Biolabs Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9887:HKG\">HKG: 9887<\/a>) reported <strong>Phase\u202f1\/2 data<\/strong> for <strong>LBL-034<\/strong> in <strong>relapsed\/refractory multiple myeloma<\/strong> at the 67th ASH Annual Meeting. The bispecific T\u2011cell engager targeting <strong>GPRC5D and CD3<\/strong> demonstrated strong efficacy with <strong>82.5% ORR<\/strong> and a favorable safety profile with no dose\u2011limiting toxicities observed up to 1,200\u202f\u03bcg\/kg.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<p><strong>LBL-034<\/strong> is a <strong>bispecific T\u2011cell engager (TCE)<\/strong> that simultaneously targets:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GPRC5D<\/strong>: A novel antigen highly expressed on multiple myeloma cells<\/li>\n\n\n\n<li><strong>CD3<\/strong>: T\u2011cell receptor component to redirect immune response<\/li>\n<\/ul>\n\n\n\n<p><strong>Design Advantages:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sub-nanomolar affinity<\/strong> for potent tumor cell engagement<\/li>\n\n\n\n<li><strong>Tumor-selective activation<\/strong> minimizes off-tumor toxicity<\/li>\n\n\n\n<li><strong>Graduated dosing<\/strong> allows for safety titration<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-phase-1-2-study-design-amp-safety\">Phase\u202f1\/2 Study Design &amp; Safety<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study Parameter<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Design<\/strong><\/td><td>Phase\u202f1\/2 dose-escalation and expansion<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Relapsed\/refractory multiple myeloma<\/td><\/tr><tr><td><strong>Dose Range Tested<\/strong><\/td><td>Up to 1,200\u202f\u03bcg\/kg<\/td><\/tr><tr><td><strong>Dose-Limiting Toxicity (DLT)<\/strong><\/td><td>None observed<\/td><\/tr><tr><td><strong>Maximum Tolerated Dose (MTD)<\/strong><\/td><td>Not reached<\/td><\/tr><tr><td><strong>Related Adverse Events<\/strong><\/td><td>All Grade\u202f1\u20112, primarily Cycle\u202f1; decreased in subsequent cycles<\/td><\/tr><tr><td><strong>Quality-of-Life Toxicities<\/strong><\/td><td>Taste, skin, nail toxicities infrequent and self-resolving<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Safety Summary<\/strong>: No treatment discontinuations due to adverse events; most AEs managed with supportive care.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-efficacy-results-400-1-200-\u03bcg-kg-dose-range-n-40\">Efficacy Results (400\u20131,200\u202f\u03bcg\/kg dose range, n=40)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Objective Response Rate (ORR)<\/strong><\/td><td><strong>82.5%<\/strong><\/td><td>Strong anti-tumor activity<\/td><\/tr><tr><td><strong>\u2265 Complete Response (CR)<\/strong><\/td><td><strong>52.5%<\/strong><\/td><td>Deep responses<\/td><\/tr><tr><td><strong>\u2265 Very Good Partial Response (VGPR)<\/strong><\/td><td><strong>72.5%<\/strong><\/td><td>High-quality responses<\/td><\/tr><tr><td><strong>MRD Negativity<\/strong><\/td><td><strong>80.0%<\/strong><\/td><td>Minimal residual disease clearance<\/td><\/tr><tr><td><strong>12\u2011Month PFS Rate<\/strong><\/td><td><strong>61.2%<\/strong><\/td><td>Durable disease control<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Dose\u2011Specific Efficacy (800\u202f\u03bcg\/kg):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ORR<\/strong>: <strong>90.9%<\/strong><\/li>\n\n\n\n<li><strong>\u2265CR<\/strong>: <strong>63.6%<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Key Insight<\/strong>: 800\u202f\u03bcg\/kg dose level shows optimal efficacy\/safety balance, likely to be recommended Phase\u202f2 dose.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-outlook\">Market Context &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Multiple Myeloma Burden<\/strong>: China has ~30,000 new cases annually; R\/R population represents ~40% (12,000 patients)<\/li>\n\n\n\n<li><strong>GPRC5D Landscape<\/strong>: Emerging target with limited competition; Talquetamab (J&amp;J) approved in US but not yet in China<\/li>\n\n\n\n<li><strong>CAR\u2011T vs. TCE<\/strong>: TCEs offer off-the-shelf convenience vs. autologous CAR\u2011T; LBL-034 positions as leading GPRC5D bispecific<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: Analysts project <strong>\u00a53-5\u202fbillion<\/strong> (\u2248\u202fUS$420-700\u202fmillion) peak sales if approved<\/li>\n\n\n\n<li><strong>Next Milestones<\/strong>: Phase\u202f2 expansion cohort ongoing; registration-enabling study initiation planned for H1\u202f2026<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding LBL-034 development timelines, clinical outcomes, and market potential. Actual results may differ due to clinical, regulatory, and competitive uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025120700022_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025120700022_c.\"><\/object><a id=\"wp-block-file--media-532fd4ce-b1c9-49bb-bdb2-619ae16efdd9\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025120700022_c.pdf\">2025120700022_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025120700022_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-532fd4ce-b1c9-49bb-bdb2-619ae16efdd9\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) reported Phase\u202f1\/2 data for LBL-034 in relapsed\/refractory multiple&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50204,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,17,4242,1974,28],"class_list":["post-50202","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-clinical-trial-results","tag-hkg-9887","tag-leads-biolabs","tag-multi-specific-antibodies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Leads Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) reported Phase\u202f1\/2 data for LBL-034 in relapsed\/refractory multiple myeloma at the 67th ASH Annual Meeting. The bispecific T\u2011cell engager targeting GPRC5D and CD3 demonstrated strong efficacy with 82.5% ORR and a favorable safety profile with no dose\u2011limiting toxicities observed up to 1,200\u202f\u03bcg\/kg.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50202\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leads Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR\" \/>\n<meta property=\"og:description\" content=\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) reported Phase\u202f1\/2 data for LBL-034 in relapsed\/refractory multiple myeloma at the 67th ASH Annual Meeting. The bispecific T\u2011cell engager targeting GPRC5D and CD3 demonstrated strong efficacy with 82.5% ORR and a favorable safety profile with no dose\u2011limiting toxicities observed up to 1,200\u202f\u03bcg\/kg.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50202\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T14:20:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-08T14:20:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0812.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50202#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50202\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Leads Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR\",\"datePublished\":\"2025-12-08T14:20:08+00:00\",\"dateModified\":\"2025-12-08T14:20:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50202\"},\"wordCount\":371,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50202#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0812.webp\",\"keywords\":[\"Academic conference\",\"Clinical trial results\",\"HKG: 9887\",\"Leads Biolabs\",\"Multi-specific antibodies\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50202#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50202\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50202\",\"name\":\"Leads Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50202#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50202#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0812.webp\",\"datePublished\":\"2025-12-08T14:20:08+00:00\",\"dateModified\":\"2025-12-08T14:20:16+00:00\",\"description\":\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) reported Phase\u202f1\\\/2 data for LBL-034 in relapsed\\\/refractory multiple myeloma at the 67th ASH Annual Meeting. The bispecific T\u2011cell engager targeting GPRC5D and CD3 demonstrated strong efficacy with 82.5% ORR and a favorable safety profile with no dose\u2011limiting toxicities observed up to 1,200\u202f\u03bcg\\\/kg.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50202#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50202\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50202#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0812.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0812.webp\",\"width\":1080,\"height\":608,\"caption\":\"Leads-Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50202#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leads Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Leads Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR - Insight, China&#039;s Pharmaceutical Industry","description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) reported Phase\u202f1\/2 data for LBL-034 in relapsed\/refractory multiple myeloma at the 67th ASH Annual Meeting. The bispecific T\u2011cell engager targeting GPRC5D and CD3 demonstrated strong efficacy with 82.5% ORR and a favorable safety profile with no dose\u2011limiting toxicities observed up to 1,200\u202f\u03bcg\/kg.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50202","og_locale":"en_US","og_type":"article","og_title":"Leads Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR","og_description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) reported Phase\u202f1\/2 data for LBL-034 in relapsed\/refractory multiple myeloma at the 67th ASH Annual Meeting. The bispecific T\u2011cell engager targeting GPRC5D and CD3 demonstrated strong efficacy with 82.5% ORR and a favorable safety profile with no dose\u2011limiting toxicities observed up to 1,200\u202f\u03bcg\/kg.","og_url":"https:\/\/flcube.com\/?p=50202","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-08T14:20:08+00:00","article_modified_time":"2025-12-08T14:20:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0812.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50202#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50202"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Leads Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR","datePublished":"2025-12-08T14:20:08+00:00","dateModified":"2025-12-08T14:20:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50202"},"wordCount":371,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50202#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0812.webp","keywords":["Academic conference","Clinical trial results","HKG: 9887","Leads Biolabs","Multi-specific antibodies"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50202#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50202","url":"https:\/\/flcube.com\/?p=50202","name":"Leads Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50202#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50202#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0812.webp","datePublished":"2025-12-08T14:20:08+00:00","dateModified":"2025-12-08T14:20:16+00:00","description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) reported Phase\u202f1\/2 data for LBL-034 in relapsed\/refractory multiple myeloma at the 67th ASH Annual Meeting. The bispecific T\u2011cell engager targeting GPRC5D and CD3 demonstrated strong efficacy with 82.5% ORR and a favorable safety profile with no dose\u2011limiting toxicities observed up to 1,200\u202f\u03bcg\/kg.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50202#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50202"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50202#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0812.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0812.webp","width":1080,"height":608,"caption":"Leads-Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50202#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Leads Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0812.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50202"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50202\/revisions"}],"predecessor-version":[{"id":50205,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50202\/revisions\/50205"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50204"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}